Rebuilding Synaptic Architecture in HIV-1 Associated Neurocognitive Disease: A Therapeutic Strategy Based on Modulation of Mixed Lineage Kinase

Neurotherapeutics

Volumn 7, Issue 4, 2010, Pages 392-398

  Gelbard, Harris A ^a   Dewhurst, Stephen ^a   Maggirwar, Sanjay B ^a   Kiebala, Michelle ^a   Polesskaya, Oksana ^a   Gendelman, Howard E ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

HIV 1; HIV 1 associated neurocognitive disease (HAND); Microglia; Mixed lineage kinase type 3; Neuroinflammation; Neurotrophins; Synapse; Tat

Indexed keywords

CEP 1347; MEMANTINE; MIXED LINEAGE KINASE 3;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME INHIBITION; HIV ASSOCIATED DEMENTIA; HUMAN; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPTIC MEMBRANE; TREATMENT OUTCOME; UPREGULATION;

EID: 77957076581     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2010.08.001     Document Type: Article

References (86)

1. Heaton R, Clifford D, Woods S, et al. HIV-associated neurocognitive impairment remains prevalent in the era of combination ART: The CHARTER Study. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 2009; Montreal, CA.
2. Neuenburg J.K., Brodt H.R., Herndier B.G., et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 31:171-177.
3. Marra C.M., Zhao Y., Clifford D.B., et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids 2009, 23:1359-1366.
4. Brennan T.P., Woods J.O., Sedaghat A.R., Siliciano J.D., Siliciano R.F., Wilke C.O. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009, 83:8470-8481.
5. Dinoso J.B., Rabi S.A., Blankson J.N., et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 2009, 83:9247-9257.
6. Yang H.C., Xing S., Shan L., et al. Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest 2009, 119:3473-3486.
7. Uthman O.A., Abdulmalik J.O. Adjunctive therapies for AIDS dementia complex. Cochrane Database Syst Rev 2008, CD006496.
8. Chang L., Ernst T., Witt M.D., et al. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003, 8:17-26.
9. Ernst T., Chang L., Jovicich J., Ames N., Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002, 59:1343-1349.
10. Ernst T., Yakupov R., Nakama H., et al. Declined neural efficiency in cognitively stable human immunodeficiency virus patients. Ann Neurol 2009, 65:316-325.
11. Anderson E.R., Gendelman H.E., Xiong H. Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 2004, 24:7194-7198.
12. Schifitto G., Navia B.A., Yiannoutsos C.T., et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids 2007, 21:1877-1886.
13. Bellizzi M.J., Lu S.M., Gelbard H.A. Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J Neuroimmune Pharmacol 2006, 1:20-31.
14. Bellizzi M.J., Lu S.M., Masliah E., Gelbard H.A. Synaptic activity becomes excitotoxic in neurons exposed to elevated levels of platelet-activating factor. J Clin Invest 2005, 115:3185-3192.
15. Ellis R., Langford D., Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 2007, 8:33-44.
16. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 2002, 3:663-672.
17. Silva R.M., Kuan C.Y., Rakic P., Burke R.E. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov Disord 2005, 20:653-664.
18. Wang L.H., Besirli C.G., Johnson E.M. Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004, 44:451-474.
19. Maroney A.C., Finn J.P., Connors T.J., et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001, 276:25302-25308.
20. Handley M.E., Rasaiyaah J., Barnett J., et al. Expression and function of mixed lineage kinases in dendritic cells. Int Immunol 2007, 19:923-933.
21. Handley M.E., Rasaiyaah J., Chain B.M., Katz D.R. Mixed lineage kinases (MLKs): a role in dendritic cells, inflammation and immunity?. Int J Exp Pathol 2007, 88:111-126.
22. Jaeschke A., Davis R.J. Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 2007, 27:498-508.
23. Sathyanarayana P., Barthwal M.K., Kundu C.N., et al. Activation of the drosophila MLK by ceramide reveals TNF-alpha and ceramide as agonists of mammalian MLK3. Mol Cell 2002, 10:1527-1533.
24. Leung I.W., Lassam N. Dimerization via tandem leucine zippers is essential for the activation of the mitogen-activated protein kinase kinase kinase, MLK-3. J Biol Chem 1998, 273:32408-32415.
25. Leung I.W., Lassam N. The kinase activation loop is the key to mixed lineage kinase-3 activation via both autophosphorylation and hematopoietic progenitor kinase 1 phosphorylation. J Biol Chem 2001, 276:1961-1967.
26. Sui Z., Fan S., Sniderhan L., et al. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J Immunol 2006, 177:702-711.
27. Mishra R., Barthwal M.K., Sondarva G., et al. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3. J Biol Chem 2007, 282:30393-30405.
28. Mota M., Reeder M., Chernoff J., Bazenet C.E. Evidence for a role of mixed lineage kinases in neuronal apoptosis. J Neurosci 2001, 21:4949-4957.
29. Savinainen A., Garcia E.P., Dorow D., Marshall J., Liu Y.F. Kainate receptor activation induces mixed lineage kinase-mediated cellular signaling cascades via post-synaptic density protein 95. J Biol Chem 2001, 276:11382-11386.
30. Lotharius J., Falsig J., van Beek J., et al. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J Neurosci 2005, 25:6329-6342.
31. Mathiasen J.R., McKenna B.A., Saporito M.S., et al. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells. Brain Res 2004, 1003:86-97.
32. Saporito M.S., Brown E.M., Miller M.S., Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999, 288:421-427.
33. Saporito M.S., Hudkins R.L., Maroney A.C. Discovery of CEP-1347/KT-7515, an inhibitor of the JNK/SAPK pathway for the treatment of neurodegenerative diseases. Prog Med Chem 2002, 40:23-62.
34. Bodner A., Maroney A.C., Finn J.P., Ghadge G., Roos R., Miller R.J. Mixed lineage kinase 3 mediates gp120IIIB-induced neurotoxicity. J Neurochem 2002, 82:1424-1434.
35. Bodner A., Toth P.T., Miller R.J. Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity. Exp Neurol 2004, 188:246-253.
36. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007, 69:1480-1490.
37. Wang J., Gigliotti F., Bhagwat S.P., Maggirwar S.B., Wright T.W. Pneumocystis stimulates MCP-1 production by alveolar epithelial cells through a JNK-dependent mechanism. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1495-L1505.
38. Saporito M.S., Thomas B.A., Scott R.W. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 2000, 75:1200-1208.
39. Wang L.H., Johnson E.M. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2008, 71:462-463.
40. Eggert D., Dash P.K., Gorantla S., et al. Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 2010, 184:746-756.
41. Glass J.D., Fedor H., Wesselingh S.L., McArthur J.C. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 1995, 38:755-762.
42. Borda J.T., Alvarez X., Mohan M., et al. CD163, a marker of perivascular macrophages, is up-regulated by microglia in simian immunodeficiency virus encephalitis after haptoglobin-hemoglobin complex stimulation and is suggestive of breakdown of the blood-brain barrier. Am J Pathol 2008, 172:725-737.
43. Fabriek B.O., Van Haastert E.S., Galea I., et al. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia 2005, 51:297-305.
44. Kim W.K., Alvarez X., Fisher J., et al. CD163 identifies perivascular macrophages in normal and viral encephalitic brains and potential precursors to perivascular macrophages in blood. Am J Pathol 2006, 168:822-834.
45. Marcondes M.C., Lanigan C.M., Burdo T.H., Watry D.D., Fox H.S. Increased expression of monocyte CD44v6 correlates with the deveopment of encephalitis in rhesus macaques infected with simian immunodeficiency virus. J Infect Dis 2008, 197:1567-1576.
46. Pulliam L., Gascon R., Stubblebine M., Mcguire D., McGrath M.S. Unique monocyte subset in patients with AIDS dementia. Lancet 1997, 349:692-695.
47. Roberts E.S., Masliah E., Fox H.S. CD163 identifies a unique population of ramified microglia in HIV encephalitis (HIVE). J Neuropathol Exp Neurol 2004, 63:1255-1264.
48. Roberts E.S., Zandonatti M.A., Watry D.D., et al. Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. Am J Pathol 2003, 162:2041-2057.
49. Anthony I.C., Bell J.E. The Neuropathology of HIV/AIDS. Int Rev Psychiatry 2008, 20:15-24.
50. Anthony I.C., Ramage S.N., Carnie F.W., Simmonds P., Bell J.E. Influence of HAART on HIV-related CNS disease and neuroinflammation. J Neuropathol Exp Neurol 2005, 64:529-536.
51. Everall I.P., Hansen L.A., Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res 2005, 8:51-61.
52. Gray F., Chretien F., Vallat-Decouvelaere A.V., Scaravilli F. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol Exp Neurol 2003, 62:429-440.
53. Abraham S., Sawaya B.E., Safak M., Batuman O., Khalili K., Amini S. Regulation of MCP-1 gene transcription by Smads and HIV-1 Tat in human glial cells. Virology 2003, 309:196-202.
54. Conant K., Garzino-Demo A., Nath A., et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A 1998, 95:3117-3121.
55. D'Aversa T.G., Yu K.O., Berman J.W. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J Neurovirol 2004, 10:86-97.
56. El-Hage N., Wu G., Ambati J., Bruce-Keller A.J., Knapp P.E., Hauser K.F. CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol 2006, 178:9-16.
57. El-Hage N., Wu G., Wang J., et al. HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 2006, 53:132-146.
58. Eugenin E.A., D'Aversa T.G., Lopez L., Calderon T.M., Berman J.W. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem 2003, 85:1299-1311.
59. Eugenin E.A., Dyer G., Calderon T.M., Berman J.W. HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia 2005, 49:501-510.
60. Lim S.P., Garzino-Demo A. The human immunodeficiency virus type 1 Tat protein up-regulates the promoter activity of the beta-chemokine monocyte chemoattractant protein 1 in the human astrocytoma cell line U-87 MG: role of SP-1, AP-1, and NF-kappaB consensus sites. J Virol 2000, 74:1632-1640.
61. McManus C.M., Weidenheim K., Woodman S.E., et al. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. Am J Pathol 2000, 156:1441-1453.
62. Sodhi A., Biswas S.K. Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation. J Interferon Cytokine Res 2002, 22:517-526.
63. Toborek M., Lee Y.W., Pu H., et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003, 84:169-179.
64. Weiss J.M., Nath A., Major E.O., Berman J.W. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol 1999, 163:2953-2959.
65. Zheng J.C., Huang Y., Tang K., et al. HIV-1-infected and/or immune-activated macrophages regulate astrocyte CXCL8 production through IL-1beta and TNF-alpha: involvement of mitogen-activated protein kinases and protein kinase R. J Neuroimmunol 2008, 200:100-110.
66. Gouwy M., Struyf S., Noppen S., et al. Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharmacol 2008, 74:485-495.
67. Gouwy M., Struyf S., Verbeke H., et al. CC chemokine ligand-2 synergizes with the nonchemokine G protein-coupled receptor ligand fMLP in monocyte chemotaxis, and it cooperates with the TLR ligand LPS via induction of CXCL8. J Leukoc Biol 2009, 86:671-680.
68. Ahmed R.A., Murao K., Imachi H., et al. c-Jun N-terminal kinases inhibitor suppresses the TNF-alpha induced MCP-1 expression in human umbilical vein endothelial cells. Endocrine 2009, 35:184-188.
69. Arndt P.G., Suzuki N., Avdi N.J., Malcolm K.C., Worthen G.S. Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. J Biol Chem 2004, 279:10883-10891.
70. Gao Y.J., Zhang L., Samad O.A., et al. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci 2009, 29:4096-4108.
71. Wolter S., Doerrie A., Weber A., et al. c-Jun controls histone modifications, NF-kappaB recruitment, and RNA polymerase II function to activate the ccl2 gene. Mol Cell Biol 2008, 28:4407-4423.
72. Young S.K., Arndt P.G. c-Jun NH2-terminal kinase regulates lipopolysaccharide-induced pulmonary mononuclear cell recruitment via CCL2. Exp Lung Res 2009, 35:682-700.
73. Cambien B., Pomeranz M., Millet M.A., Rossi B., Schmid-Alliana A. Signal transduction involved in MCP-1-mediated monocytic transendothelial migration. Blood 2001, 97:359-366.
74. Werle M., Schmal U., Hanna K., Kreuzer J. MCP-1 induces activation of MAP-kinases ERK, JNK and p38 MAPK in human endothelial cells. Cardiovasc Res 2002, 56:284-292.
75. Sui Z., Kovacs A.D., Maggirwar S.B. Recruitment of active glycogen synthase kinase-3 into neuronal lipid rafts. Biochem Biophys Res Commun 2006, 345:1643-1648.
76. New D.R., Maggirwar S.B., Epstein L.G., Dewhurst S., Gelbard H.A. HIV-1 Tat induces neuronal death via tumor necrosis factor-alpha and activation of non-N-methyl-D-aspartate receptors by a NFkappaB-independent mechanism. J Biol Chem 1998, 273:17852-17858.
77. Asami T., Ito T., Fukumitsu H., Nomoto H., Furukawa Y., Furukawa S. Autocrine activation of cultured macrophages by brain-derived neurotrophic factor. Biochem Biophys Res Commun 2006, 344:941-947.
78. Batchelor P.E., Liberatore G.T., Wong J.Y., et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 1999, 19:1708-1716.
79. Lai A.Y., Todd K.G. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 2008, 56:259-270.
80. Nakajima K., Honda S., Tohyama Y., Imai Y., Kohsaka S., Kurihara T. Neurotrophin secretion from cultured microglia. J Neurosci Res 2001, 65:322-331.
81. Mizoguchi Y., Monji A., Kato T., et al. Brain-derived neurotrophic factor induces sustained elevation of intracellular Ca2+ in rodent microglia. J Immunol 2009, 183:7778-7786.
82. Nakajima K., Kikuchi Y., Ikoma E., et al. Neurotrophins regulate the function of cultured microglia. Glia 1998, 24:272-289.
83. Pedraza N., Rafel M., Navarro I., Encinas M., Aldea M., Gallego C. Mixed lineage kinase phosphorylates transcription factor E47 and inhibits TrkB expression to link neuronal death and survival pathways. J Biol Chem 2009, 284:32980-32988.
84. Wang L.H., Paden A.J., Johnson E.M. Mixed-lineage kinase inhibitors require the activation of Trk receptors to maintain long-term neuronal trophism and survival. J Pharmacol Exp Ther 2005, 312:1007-1019.
85. Nosheny R.L., Ahmed F., Yakovlev A., et al. Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci 2007, 25:2275-2284.
86. Mocchetti I., Bachis A. Brain-derived neurotrophic factor activation of TrkB protects neurons from HIV-1/gp120-induced cell death. Crit Rev Neurobiol 2004, 16:51-57.